Molecular Detection

Company Overview

Snapshot

Founded in February 2007, Molecular Detection operated with 11–50 employees, focusing on developing rapid diagnostic solutions. The company's status became Non Active in October 2016.

Business overview

Molecular Detection is a Health Tech & Life Sciences company specializing in medical devices, particularly diagnostics. The company developed SEPSIS-xxpress, a hospital-based instrument designed for rapid sepsis diagnosis and pathogen profiling. This technology aims to provide doctors with specific pathogen and antibiotic-resistance information in the critical early hours of infection, serving the healthcare and provider markets in geomarkets such as China and the United States.

Company Intelligence Q&A

What is Molecular Detection's primary product?

Molecular Detection developed SEPSIS-xxpress, a hospital-based instrument for rapid sepsis diagnosis and pathogen profiling, designed to identify specific pathogens and antibiotic-resistance profiles.

When was Molecular Detection founded?

Molecular Detection was founded in February 2007.

What is the operational status of Molecular Detection?

Molecular Detection's status became Non Active in October 2016.

Which markets does Molecular Detection target?

Molecular Detection targets the healthcare and provider markets, with geomarket focus areas including China and the United States.

What problem does SEPSIS-xxpress address?

SEPSIS-xxpress aims to provide rapid and comprehensive diagnosis for sepsis, enabling doctors to quickly identify pathogens and their antibiotic-resistance profiles for timely treatment.